Litcius/Paper detail

Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial

Ildiko Lingvay, Sara Johanna Bergenheim, John B. Buse, Paula Freitas, W. Timothy Garvey, Nina M. Harder‐Lauridsen, Julio Rosenstock, Kushal Sahu, Sean Wharton

2025The Lancet Diabetes & Endocrinology28 citationsDOI

Topics & Concepts

MedicineSemaglutideType 2 diabetesObesityInternal medicineDiabetes mellitusEndocrinologyClinical trialMEDLINEPhase (matter)Phases of clinical researchWeight lossDiabetes Treatment and ManagementBariatric Surgery and OutcomesHyperglycemia and glycemic control in critically ill and hospitalized patients
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial | Litcius